Posted by Michael Wonder on 15 Mar 2021
Aurinia announces positive cost effectiveness assessment of Lupkynis (voclosporin) in latest ICER draft evidence report
15 March 2021 -Aurinia Pharmaceuticals today announced a favorable assessment regarding the cost-effectiveness and value of Lupkynis (voclosporin), based on an independent analysis issued by ICER in a revised Evidence Report issued on 12 March 2021.
The report finds that Lupkynis represents an important new treatment option for patients living with lupus nephritis and at the estimated net price, determined the therapy to be priced in alignment with ICER’s recommended health-benefit price benchmark ranges.
